OM:BIOA BBiotechs
BioArctic (OM:BIOA B) Valuation Check After Leqembi Priority Review Progress And Royalty Growth
BioArctic (OM:BIOA B) is back in focus after partner Eisai secured Priority Review in China for a subcutaneous Leqembi autoinjector, while recent Leqembi driven royalties to BioArctic grew sharply year on year.
See our latest analysis for BioArctic.
BioArctic’s partner driven Leqembi news arrives as the share price sits at SEK322.2, with a 5.02% 7 day share price return, a 6.01% 30 day share price decline and a 51.69% 1 year total shareholder return, which points to momentum that has cooled...